Initially, 5 mg/day. Increase dose by 5 mg/day to a target dose of 20 mg/day.
Wait at least 1 week between dosage changes. Doses >5 mg/day should be given in
2 divided doses.
Memantine pharmacokinetics were evaluated following single oral
administration of 20 mg memantine HCl in 8 subjects with mild renal
impairment (creatinine clearance, CLcr, >50 – 80 mL/min), 8 subjects
with moderate renal impairment (CLcr 30 – 49 mL/min), 7 subjects with
severe renal impairment (CLcr 5 – 29 mL/min) and 8 healthy subjects (CLcr
> 80 mL/min) matched as closely as possible by age, weight and gender to
the subjects with renal impairment. Mean AUC0- increased by 4%, 60%,
and 115% in subjects with mild, moderate, and severe renal impairment,
respectively, compared to healthy subjects. The terminal elimination
half-life increased by 18%, 41%, and 95% in subjects with mild,
moderate, and severe renal impairment, respectively, compared to healthy
[Mild to Moderate impairment]: No dosage adjustment is
recommended for patients with mild and moderate renal impairment.
[Severe impairment]: A target dose of 5 mg BID is
recommended in patients with severe renal impairment (creatinine
clearance of 5 – 29 mL/min based on the Cockroft-Gault equation):
National Institutes of Health, U.S. National Library of Medicine,
DailyMed Database. Provides access to the latest drug monographs submitted to the
Food and Drug Administration (FDA). Please review the latest applicable package insert for
additional information and possible updates. A local search
option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical
judgment. Neither GlobalRPh Inc. nor any other party involved in the
preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.PLEASE READ THE DISCLAIMER
BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU
AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read